Managementul efectelor COVID-19 asupra simptomelor tractului urinar inferior la pacientii cu hiperplazie benigna de prostata
Management in Health · 2023
DOI: 10.5233/1nf2bz33 ↗Abstract
INTRODUCTION. The novel sever acute respiratory syndrome coronavirus2 (SARS-CoV-2) was initial discovered in Wuhan, China in 2019, and since 2020it had a major impact on medical practice. Since its discovery it has spreadthroughout the entire world and the coronavirus disease (COVID-19) wasdeclared a pandemic by the World Health Organization (WHO). At the beginningit was believed that is only a pneumonia with flu like symptoms, but as new casesemerged other symptoms appeared among COVID-19 patients affectingcardiovascular system, gastrointestinal tract and kidney. The interaction betweenACE receptors and virus was supposed to be the cause of the various symptoms.OBJECTIVES. The aim of the study was to see the effect of SARS-CoV-2infection on patients with benign prostate hyperplasia (BPH), between acuteinfection and after 1 month regarding urological symptoms and to find predictorsfor urine retention in such patients.MATERIALS AND METHODS. We evaluated all male patients admitted inour hospital with SARS-CoV-2 infection who expressed different forms of COVID-19. We enrolled patients who were previously diagnosed with BPH. We gatheredinformation of their condition prior to infection as prostate volume, postvoidingresidual urine, International Prostate Symptom Score (IPSS) and othercomorbidities. All enrolled patients were assessed using clinical examinationdigital rectum examination (DRE), pelvi-abdominal ultrasonography for prostatevolume and postvoiding residual urine (PVR) and IPSS for lower urinary tractsymptoms. We performed a multivariate analysis to detect the correlation betweenurinary symptoms and scores and COVID-19 disease.RESULTS. Thirty-tree patients, who were prior diagnosed with BPH, wereenrolled. The mean age (±SD) was 71.85 ± 9.12. In the pre and post COVID-19group, the mean IPSS was 11.76 ± 5.28 and 18.97 ± 7.99 (P
EUVIMED